Nurix Therapeutics (NRIX) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRIX shares.
View NRIX analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued twelve-month price objectives for Nurix Therapeutics' stock. Their NRIX share price forecasts range from $11.00 to $53.00. On average, they anticipate the company's share price to reach $29.70 in the next year. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts.

Nurix Therapeutics' stock was trading at $10.98 on January 1st, 2023. Since then, NRIX stock has decreased by 7.4% and is now trading at $10.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023.
View our NRIX earnings forecast.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings data on Thursday, October, 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.02. The company had revenue of $10.25 million for the quarter, compared to analyst estimates of $8.73 million. Nurix Therapeutics had a negative net margin of 428.29% and a negative trailing twelve-month return on equity of 60.17%.

ETFs with the largest weight of Nurix Therapeutics (NASDAQ:NRIX) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

(NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."

Nurix Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.04%), Wasatch Advisors LP (6.69%), Price T Rowe Associates Inc. MD (5.45%), ARK Investment Management LLC (4.72%), State Street Corp (4.71%) and Pictet Asset Management SA (2.24%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff.
View institutional ownership trends.

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NRIX stock can currently be purchased for approximately $10.17.

Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $482.46 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($3.53) on an earnings per share basis.

The company employs 242 workers across the globe.

The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com.